Kodiak Sciences Reports Positive GLOW2 Results for Zenkuda
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Source: PRnewswire
Kodiak Sciences' stock surged 44.03% in pre-market trading, reaching a 52-week high, following the announcement of positive results from the GLOW2 Phase 3 trial for Zenkuda.
The GLOW2 study demonstrated that 62.5% of diabetic retinopathy patients treated with Zenkuda achieved a ≥2-step improvement in DRSS score, significantly outperforming the 3.3% in the control group. This strong efficacy, coupled with a favorable safety profile and plans for expedited BLA submission, positions Kodiak for potential market expansion and increased investor confidence.
The positive trial results not only enhance Zenkuda's market acceptance but also suggest a promising future for Kodiak Sciences in the ophthalmic drug sector, potentially leading to greater financial backing and research opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KOD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KOD
Wall Street analysts forecast KOD stock price to fall
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 31.060
Low
14.00
Averages
27.86
High
50.00
Current: 31.060
Low
14.00
Averages
27.86
High
50.00
About KOD
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kodiak Sciences CFO Sells 30,000 Shares in Routine Transaction
- Transaction Overview: Kodiak Sciences CFO John A. Borgeson sold 30,000 shares through option exercise and immediate disposition on June 4, 2026, with a transaction value of approximately $1 million, indicating ongoing liquidity management within the company.
- Ownership Change: Post-transaction, Borgeson's direct holdings decreased by 12.40% to 211,930 shares, with a direct equity value of about $7.24 million, suggesting he remains heavily invested in the company's future performance.
- Transaction Structure: The entire sale of 30,000 shares was executed following option exercise and immediately sold in the open market under a pre-established 10b5-1 trading plan, reflecting routine financial planning rather than a shift in market sentiment.
- Company Outlook: Kodiak Sciences ended Q1 2026 with $169.5 million in cash, indicating that existing resources should fund operations into 2027, with future investment focus on upcoming clinical trial data, particularly advancements in therapies for retinal diseases.
See More
Kodiak Sciences CFO Sells 30,000 Shares for $1.02 Million
- Executive Stock Sale: Kodiak Sciences CFO John Borgeson sold 30,000 shares on June 4, 2026, for approximately $1.02 million, reducing his direct holdings to 211,930 shares, indicating his continued investment in the company's future.
- Options Exercise and Sale: The transaction was a derivative one where Borgeson exercised 30,000 options and immediately sold the shares, reflecting adherence to a prearranged Rule 10b5-1 trading plan, suggesting routine financial planning rather than a market warning signal.
- Company Financial Health: Kodiak ended Q1 2026 with $169.5 million in cash, indicating that existing resources should fund operations into 2027, showcasing the company's financial stability amid clinical advancements.
- Clinical Milestone Outlook: As the company advances towards regulatory submissions for KSI-301, it expects to release Phase 3 DAYBREAK study data in September and Phase 3 PEAK results for KSI-101 in Q4, with the market eagerly anticipating these upcoming clinical data.
See More
Kodiak Sciences CEO to Present at Jefferies Global Healthcare Conference
- Presentation Schedule: Kodiak Sciences CEO Victor Perlroth, M.D. will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 11:40 AM ET, highlighting the company's advancements in retinal therapeutics.
- Webcast Availability: The presentation will be live-streamed on Kodiak's website under the 'Events and Presentations' section, with a replay available for a limited time post-event, ensuring that investors unable to attend can still access critical information.
- Company Overview: Kodiak Sciences is a precommercial biotechnology firm focused on retinal diseases, committed to researching and commercializing transformative therapeutics aimed at addressing the leading causes of blindness globally, showcasing its innovative potential in the healthcare sector.
- Clinical Program Development: The company is advancing three late-stage clinical programs, including Zenkuda™, KSI-501, and KSI-101, demonstrating its robust capabilities and promising market outlook in retinal drug development.
See More
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
- Conference Presentation: Kodiak Sciences CEO Victor Perlroth will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 11:40 AM ET, highlighting the company's advancements in retinal therapeutics.
- Webcast Availability: The presentation will be live-streamed on Kodiak's website under the 'Events and Presentations' section, with a replay available for a limited time post-event, ensuring that investors unable to attend can still access the information.
- Company Overview: Kodiak Sciences is a precommercial biotechnology firm focused on retinal therapeutics, committed to researching and commercializing transformative therapies aimed at preventing and treating leading causes of blindness globally, showcasing its innovative capabilities in the biotech sector.
- Clinical Program Development: The company is advancing three late-stage clinical programs, including Zenkuda™, KSI-501, and KSI-101, demonstrating its strong expertise and market potential in retinal drug development.
See More
Boxer Capital Increases Stake in Kodiak Sciences Amid Strong Performance
- Stake Increase: Boxer Capital Management increased its stake in Kodiak Sciences by 225,000 shares during Q1 2026, with an estimated transaction value of $5.81 million, indicating strong confidence in the company's future prospects.
- Market Performance: As of May 14, 2026, Kodiak Sciences shares were priced at $38.70, reflecting a staggering 1,000% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its potential.
- Financial Position: Kodiak Sciences reported a market value of $51.88 million at the end of Q1, despite a quarterly net loss of $58.2 million; however, the company has $169.5 million in cash, which is expected to fund operations into 2027.
- Clinical Developments: The company is set to announce several clinical trial results, including top-line data for wet AMD in September, and positive outcomes could further drive stock price increases, attracting more investor interest.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Kodiak Sciences CFO Sells 30,000 Shares in Routine Transaction
- Transaction Overview: Kodiak Sciences CFO John A. Borgeson sold 30,000 shares through option exercise and immediate disposition on June 4, 2026, with a transaction value of approximately $1 million, indicating ongoing liquidity management within the company.
- Ownership Change: Post-transaction, Borgeson's direct holdings decreased by 12.40% to 211,930 shares, with a direct equity value of about $7.24 million, suggesting he remains heavily invested in the company's future performance.
- Transaction Structure: The entire sale of 30,000 shares was executed following option exercise and immediately sold in the open market under a pre-established 10b5-1 trading plan, reflecting routine financial planning rather than a shift in market sentiment.
- Company Outlook: Kodiak Sciences ended Q1 2026 with $169.5 million in cash, indicating that existing resources should fund operations into 2027, with future investment focus on upcoming clinical trial data, particularly advancements in therapies for retinal diseases.
See More
Kodiak Sciences CFO Sells 30,000 Shares for $1.02 Million
- Executive Stock Sale: Kodiak Sciences CFO John Borgeson sold 30,000 shares on June 4, 2026, for approximately $1.02 million, reducing his direct holdings to 211,930 shares, indicating his continued investment in the company's future.
- Options Exercise and Sale: The transaction was a derivative one where Borgeson exercised 30,000 options and immediately sold the shares, reflecting adherence to a prearranged Rule 10b5-1 trading plan, suggesting routine financial planning rather than a market warning signal.
- Company Financial Health: Kodiak ended Q1 2026 with $169.5 million in cash, indicating that existing resources should fund operations into 2027, showcasing the company's financial stability amid clinical advancements.
- Clinical Milestone Outlook: As the company advances towards regulatory submissions for KSI-301, it expects to release Phase 3 DAYBREAK study data in September and Phase 3 PEAK results for KSI-101 in Q4, with the market eagerly anticipating these upcoming clinical data.
See More
Kodiak Sciences CEO to Present at Jefferies Global Healthcare Conference
- Presentation Schedule: Kodiak Sciences CEO Victor Perlroth, M.D. will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 11:40 AM ET, highlighting the company's advancements in retinal therapeutics.
- Webcast Availability: The presentation will be live-streamed on Kodiak's website under the 'Events and Presentations' section, with a replay available for a limited time post-event, ensuring that investors unable to attend can still access critical information.
- Company Overview: Kodiak Sciences is a precommercial biotechnology firm focused on retinal diseases, committed to researching and commercializing transformative therapeutics aimed at addressing the leading causes of blindness globally, showcasing its innovative potential in the healthcare sector.
- Clinical Program Development: The company is advancing three late-stage clinical programs, including Zenkuda™, KSI-501, and KSI-101, demonstrating its robust capabilities and promising market outlook in retinal drug development.
See More
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
- Conference Presentation: Kodiak Sciences CEO Victor Perlroth will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 11:40 AM ET, highlighting the company's advancements in retinal therapeutics.
- Webcast Availability: The presentation will be live-streamed on Kodiak's website under the 'Events and Presentations' section, with a replay available for a limited time post-event, ensuring that investors unable to attend can still access the information.
- Company Overview: Kodiak Sciences is a precommercial biotechnology firm focused on retinal therapeutics, committed to researching and commercializing transformative therapies aimed at preventing and treating leading causes of blindness globally, showcasing its innovative capabilities in the biotech sector.
- Clinical Program Development: The company is advancing three late-stage clinical programs, including Zenkuda™, KSI-501, and KSI-101, demonstrating its strong expertise and market potential in retinal drug development.
See More
Boxer Capital Increases Stake in Kodiak Sciences Amid Strong Performance
- Stake Increase: Boxer Capital Management increased its stake in Kodiak Sciences by 225,000 shares during Q1 2026, with an estimated transaction value of $5.81 million, indicating strong confidence in the company's future prospects.
- Market Performance: As of May 14, 2026, Kodiak Sciences shares were priced at $38.70, reflecting a staggering 1,000% increase over the past year, significantly outperforming the S&P 500's 25% gain, showcasing market recognition of its potential.
- Financial Position: Kodiak Sciences reported a market value of $51.88 million at the end of Q1, despite a quarterly net loss of $58.2 million; however, the company has $169.5 million in cash, which is expected to fund operations into 2027.
- Clinical Developments: The company is set to announce several clinical trial results, including top-line data for wet AMD in September, and positive outcomes could further drive stock price increases, attracting more investor interest.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
